Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - sprycel
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp9ef90a3b084c8b791046c3e0616188b5
identifier: http://ema.europa.eu/identifier
/EU/1/06/363/004
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: SPRYCEL 20 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-9ef90a3b084c8b791046c3e0616188b5
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/06/363/004
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - sprycel
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
SPRYCEL contains the active substance dasatinib. This medicine is used to treat chronic myeloid leukaemia (CML) in adults, adolescents and children at least 1 year of age. Leukaemia is a cancer of white blood cells. These white cells usually help the body to fight infection. In people with CML, white cells called granulocytes start growing out of control. SPRYCEL inhibits the growth of these leukaemic cells.
SPRYCEL is also used to treat Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) in adults, adolescents and children at least 1 year of age, and lymphoid blast CML in adults who are not benefiting from prior therapies. In people with ALL, white cells called lymphocytes multiply too quickly and live too long. SPRYCEL inhibits the growth of these leukaemic cells.
If you have any questions about how SPRYCEL works or why this medicine has been prescribed for you, ask your doctor.
Do not take SPRYCEL
Warnings and precautions Talk to your doctor or pharmacist before using SPRYCEL
if you are taking medicines to thin the blood or prevent clots (see "Other medicines and SPRYCEL")
if you have a liver or heart problem, or used to have one
if you start having difficulty breathing, chest pain, or a cough when taking SPRYCEL: this may be a sign of fluid retention in the lungs or chest (which can be more common in patients aged 65 years and older), or due to changes in the blood vessels supplying the lungs
if you have ever had or might now have a hepatitis B infection. This is because SPRYCEL could cause hepatitis B to become active again, which can be fatal in some cases. Patients will be carefully checked by their doctor for signs of this infection before treatment is started.
if you experience bruising, bleeding, fever, fatigue and confusion when taking SPRYCEL, contact your doctor. This may be a sign of damage to blood vessels known as thrombotic microangiopathy (TMA).
Your doctor will regularly monitor your condition to check whether SPRYCEL is having the desired effect. You will also have blood tests regularly while you are taking SPRYCEL.
Children and adolescents Do not give this medicine to children younger than one year of age. There is limited experience with the use of SPRYCEL in this age group. Bone growth and development will be closely monitored in children taking SPRYCEL.
Other medicines and SPRYCEL Tell your doctor if you are taking, have recently taken or might take any other medicines.
SPRYCEL is mainly handled by the liver. Certain medicines may interfere with the effect of SPRYCEL when taken together.
These medicines are not to be used with SPRYCEL:
Do not take medicines that neutralise stomach acids (antacids such as aluminium hydroxide or magnesium hydroxide) in the 2 hours before or 2 hours after taking SPRYCEL.
Tell your doctor if you are taking medicines to thin the blood or prevent clots.
SPRYCEL with food and drink Do not take SPRYCEL with grapefruit or grapefruit juice.
Pregnancy and breast-feeding If you are pregnant or think you may be pregnant, tell your doctor immediately. SPRYCEL is not to be used during pregnancy unless clearly necessary. Your doctor will discuss with you the potential risk of taking SPRYCEL during pregnancy. Both men and women taking SPRYCEL will be advised to use effective contraception during treatment.
If you are breast-feeding, tell your doctor. You should stop breast-feeding while you are taking SPRYCEL.
Driving and using machines Take special care when driving or using machines in case you experience side effects such as dizziness and blurred vision.
SPRYCEL contains lactose If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
SPRYCEL will only be prescribed to you by a doctor with experience in treating leukaemia. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. SPRYCEL is prescribed for adults and children at least 1 year of age.
The starting dose recommended for adult patients with chronic phase CML is 100 mg once a day.
The starting dose recommended for adult patients with accelerated or blast crisis CML or Ph+ ALL is 140 mg once a day.
Dosing for children with chronic phase CML or Ph+ ALL is on the basis of body weight. SPRYCEL is administered orally once daily in the form of either SPRYCEL tablets or SPRYCEL powder for oral suspension. SPRYCEL tablets are not recommended for patients weighing less than 10 kg. The powder for oral suspension should be used for patients weighing less than 10 kg and patients who cannot swallow tablets. A change in dose may occur when switching between formulations (i.e., tablets and powder for oral suspension), so you should not switch from one to the other.
Your doctor will decide the right formulation and dose based on your weight, any side effects and response to treatment. The starting dose of SPRYCEL for children is calculated by body weight as shown below:
Body Weight (kg)a Daily Dose (mg) 10 to less than 20 kg 40 mg 20 to less than 30 kg 60 mg 30 to less than 45 kg 70 mg at least 45 kg 100 mg a The tablet is not recommended for patients weighing less than 10 kg; the powder for oral suspension should be used for these patients.
There is no dose recommendation for SPRYCEL with children under 1 year of age.
Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose, or even stopping treatment briefly. For higher or lower doses, you may need to take combinations of the different tablet strengths.
The tablets may come in packs with calendar blisters. These are blisters showing the days of the week. There are arrows to show the next tablet to be taken according to your treatment schedule.
How to take SPRYCEL Take your tablets at the same time every day. Swallow the tablets whole. Do not crush, cut or chew them. Do not take dispersed tablets. You cannot be sure you will receive the correct dose if you crush, cut, chew or disperse the tablets. SPRYCEL tablets can be taken with or without a meal.
Special handling instructions for SPRYCEL It is unlikely that the SPRYCEL tablets will get broken. But if they do, persons other than the patient should use gloves when handling SPRYCEL.
How long to take SPRYCEL Take SPRYCEL daily until your doctor tells you to stop. Make sure you take SPRYCEL for as long as it is prescribed.
If you take more SPRYCEL than you should If you have accidentally taken too many tablets, talk to your doctor immediately. You may require medical attention.
If you forget to take SPRYCEL Do not take a double dose to make up for a forgotten tablet. Take the next scheduled dose at the regular time.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following can all be signs of serious side effects:
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
heart (angina), low blood pressure, narrowing of airway that may cause breathing difficulties, asthma, increased blood pressure in the arteries (blood vessels) of the lungs
Rare side effects (may affect up to 1 in 1,000 people)
Other side effects that have been reported with frequency not known (cannot be estimated from the available data)
Inflammation of the lungs
Bleeding in the stomach or bowels that can cause death
Recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection)
A reaction with fever, blisters on the skin, and ulceration of the mucous membranes
Disease of the kidneys with symptoms including oedema and abnormal laboratory test results such as protein in the urine and low protein level in the blood
Damage to blood vessels known as thrombotic microangiopathy (TMA), including decreased red blood cell count, decreased platelets, and formation of blood clots
Your doctor will check for some of these effects during your treatment.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Annexe V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle label, blister or carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What SPRYCEL contains
SPRYCEL 50 mg: the film-coated tablet is white to off-white, biconvex, oval with BMS debossed on one side and 528 on the other side.
SPRYCEL 70 mg: the film-coated tablet is white to off-white, biconvex, round with BMS debossed on one side and 524 on the other side.
SPRYCEL 80 mg: the film-coated tablet is white to off-white, biconvex, triangular with BMS 80
debossed on one side and 855 on the other side.
SPRYCEL 100 mg: the film-coated tablet is white to off-white, biconvex, oval with BMS 100
debossed on one side and 852 on the other side.
SPRYCEL 140 mg: the film-coated tablet is white to off-white, biconvex, round with BMS 140
debossed on one side and 857 on the other side.
SPRYCEL 20 mg, 50 mg or 70 mg film-coated tablets are available in cartons containing 56 film-coated tablets in 4 calendar blisters of 14 film-coated tablets each, and in cartons containing 60 x 1 film-coated tablets in perforated unit dose blisters. They are also available in bottles with child-resistant closure containing 60 film-coated tablets. Each carton contains one bottle.
SPRYCEL 80 mg, 100 mg or 140 mg film-coated tablets are available in cartons containing 30 x 1 film-coated tablets in perforated unit dose blisters. They are also available in bottles with child-resistant closure containing 30 film-coated tablets. Each carton contains one bottle.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Bristol-Myers Squibb Pharma EEIG Plaza Blanchardstown Corporate Park 2 Dublin 15, D15 TIreland
Manufacturer Swords Laboratories Unlimited Company T/A Bristol-Myers Squibb Pharmaceutical Operations, External Manufacturing Plaza Blanchardstown Corporate Park 2 Dublin 15, D15 TIreland
CATALENT ANAGNI S.R.L. Loc. Fontana del Ceraso snc Strada Provinciale 12 Casilina, 03012 Anagni (FR) Italy
This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-9ef90a3b084c8b791046c3e0616188b5
Resource Composition:
Generated Narrative: Composition composition-en-9ef90a3b084c8b791046c3e0616188b5
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/06/363/004status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - sprycel
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp9ef90a3b084c8b791046c3e0616188b5
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp9ef90a3b084c8b791046c3e0616188b5
identifier:
http://ema.europa.eu/identifier
/EU/1/06/363/004type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: SPRYCEL 20 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en